Biovest International spins off Cell Culture Company to focus on bioreactors and bioService solutions
Biovest International Inc. will spin off its instrument and contract manufacturing offerings into a single wholly-owned subsidiary named “Cell Culture Company, LLC.” Cell Culture Company will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries.
Since the late 1990s, Biovest’s primary focus has been the commercialization of personalized immunotherapies. That work will continue under the Biovest name. “The spin-off of Cell Culture Company will ensure that our instrument and CMO customers will be better served through increased focus and investment,” says Cell Culture Company President Christiaan Engstrom.
For over 30 years, Biovest has been delivering innovative, cost effective, and scalable GMP custom mammalian cell and protein production and services solutions, from pre-clinical to commercial stages in mg to kg quantities. “It is our goal to be recognized as a preferred partner and industry leader in bioreactor technology and cell culture services,” says Mr. Engstrom.
Cell Culture Company delivers value through:
Cell Culture Company will remain located in the Minneapolis, Minnesota area in the same facility it has occupied since the 1980s. The 33,000 sq ft location is home to the corporate offices, bioreactor manufacturing operations, and a distribution center, as well as an FDA-compliant custom mammalian and protein production laboratory.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.